Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Prospective, Controlled, Single-center, Open-label Phase II Clinical Trial Aimed at Evaluating the Safety and Efficacy of Autologous Mesenchymal Stem Cell Therapy for Lower Limb Ulcers in Patients With Critical Limb Ischemia

NCT06326203 is registered in ClinicalTrials.gov with UPECLIN HC FM Botucatu Unesp as lead sponsor.

NCT NCT06326203
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06326203 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Prospective, Controlled, Single-center, Open-label Phase II Clinical Trial Aimed at Evaluating the Safety and Efficacy of Autologous Mesenchymal Stem Cell Therapy for Lower Limb Ulcers in Patients With Critical Limb Ischemia
Lead sponsor
UPECLIN HC FM Botucatu Unesp
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
June 1, 2026
Completion date
March 31, 2028
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

leg ulcer, peripheral arterial disease